XML 56 R46.htm IDEA: XBRL DOCUMENT
v3.23.2

COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) shares in Millions |  | 1 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | --- | ---
Dec. 30, 2021 USD ($) shares | May 31, 2023 USD ($) | Aug. 31, 2022 USD ($) product | Dec. 31, 2021 USD ($) | Dec. 31, 2016 USD ($) product | Jun. 30, 2023 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2022 USD ($)
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  | $ 5,998,766 | $ 6,046,670 | $ 12,613,482 | $ 13,878,939
Research plan and budget, expected costs |  | $ 3,500,000 | $ 3,000,000 |  |  |  |  |  |
License Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
License agreement milestone payments (up to) |  |  | $ 452,000,000 |  |  |  |  |  |
Developmental milestone approvals, number of products (at least) | product |  |  | 3 |  |  |  |  |  |
Advance written notice required to terminate agreement |  |  |  |  |  |  |  | 90 days |
Northwestern University | License Agreement |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Upfront non-creditable one-time license issuance fee payment |  |  |  |  | $ 75,000 |  |  |  |
Annual license maintenance fee payable |  |  |  |  | 20,000 |  |  |  |
Consideration payable for rights grant |  |  |  |  | $ 5,300,000 |  |  |  |
Minimum number of product covered under license agreement | product |  |  |  |  | 1 |  |  |  |
Northwestern University | License Agreement | Maximum |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Royalty obligation period |  |  |  |  | 10 years |  |  |  |
AstraZeneca |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Upfront cash payment | $ 5,000,000 |  |  |  |  |  |  |  |
License agreement, consideration (in shares) | shares | 7.3 |  |  |  |  |  |  |  |
Days immediately preceding the execution date | 30 days |  |  |  |  |  |  |  |
Research and development |  |  |  | $ 12,300,000 |  |  |  |  |
License agreement milestone payments (up to) | $ 203,000,000 |  |  |  |  |  |  |  |
Lundbeck |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
First payment due upon completion of first phase | $ 3,000,000 |  |  |  |  |  |  |  |

X
- Definition Annual license maintenance fee payable. + References No definition available. + Details
Name: | ovid_AnnualLicenseMaintenanceFeePayable
Namespace Prefix: | ovid_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration and Option Agreement, Research Plan And Budget, Expected Costs + References No definition available. + Details
Name: | ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts
Namespace Prefix: | ovid_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Common Stock Issuance , Period Immediately Preceding Execution Date + References No definition available. + Details
Name: | ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate
Namespace Prefix: | ovid_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Consideration payable for rights grant. + References No definition available. + Details
Name: | ovid_ConsiderationPayableForRightsGrant
Namespace Prefix: | ovid_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition First payment due upon completion of first phase. + References No definition available. + Details
Name: | ovid_FirstPaymentDueUponCompletionOfFirstPhase
Namespace Prefix: | ovid_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement, Consideration, Shares Issued + References No definition available. + Details
Name: | ovid_LicenseAgreementConsiderationSharesIssued
Namespace Prefix: | ovid_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition License Agreement, Development Milestone Approvals, Product Threshold + References No definition available. + Details
Name: | ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold
Namespace Prefix: | ovid_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Global commercial and regulatory milestone payments. + References No definition available. + Details
Name: | ovid_LicenseAgreementMilestonePayments
Namespace Prefix: | ovid_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License Agreement, Termination, Advance Notice Period + References No definition available. + Details
Name: | ovid_LicenseAgreementTerminationAdvanceNoticePeriod
Namespace Prefix: | ovid_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum number of product covered under license agreement + References No definition available. + Details
Name: | ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement
Namespace Prefix: | ovid_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Obligation, Term + References No definition available. + Details
Name: | ovid_RoyaltyObligationTerm
Namespace Prefix: | ovid_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront Cash Payment + References No definition available. + Details
Name: | ovid_UpfrontCashPayment
Namespace Prefix: | ovid_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront non-creditable one-time license issuance fee payment. + References No definition available. + Details
Name: | ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment
Namespace Prefix: | ovid_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ovid_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ovid_AstrazenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ovid_HLundbeckASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |